{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:33:15Z","timestamp":1761658395168,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-109-2321-B-002-034"],"award-info":[{"award-number":["MOST-109-2321-B-002-034"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jmii.2021.03.014","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T20:04:06Z","timestamp":1622837046000},"page":"901-908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-3054","authenticated-orcid":false,"given":"Wei-Cheng","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzen-Kwan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa-Fa","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Min","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2021.03.014_bib1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2009.01.004","article-title":"Hepatitis D: thirty years after","volume":"50","author":"Rizzetto","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jmii.2021.03.014_bib2","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","article-title":"Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU\/mL","volume":"18","author":"Tseng","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jmii.2021.03.014_bib3","doi-asserted-by":"crossref","first-page":"a021550","DOI":"10.1101\/cshperspect.a021550","article-title":"Hepatitis D virus coinfection and superinfection","volume":"4","author":"Negro","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jmii.2021.03.014_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12985-017-0845-y","article-title":"Hepatitis delta: virological and clinical aspects","volume":"14","author":"Botelho-Souza","year":"2017","journal-title":"Virol J"},{"key":"10.1016\/j.jmii.2021.03.014_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","article-title":"Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead","volume":"7","author":"Wedemeyer","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jmii.2021.03.014_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2021.03.014_bib7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jmii.2021.03.014_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1017\/S0950268818001942","article-title":"Hepatitis delta virus and hepatocellular carcinoma: an update","volume":"146","author":"Romeo","year":"2018","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jmii.2021.03.014_bib9","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2021.03.014_bib10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/hep.1840040324","article-title":"\u03b4 agent infection in patients with chronic liver diseases and hepatocellular carcinoma-an infrequent finding in Taiwan","volume":"4","author":"Chen","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.jmii.2021.03.014_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kjms.2011.10.027","article-title":"Towards the eradication of hepatitis B in Taiwan","volume":"28","author":"Wait","year":"2012","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jmii.2021.03.014_bib12","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/hep.27742","article-title":"Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program","volume":"61","author":"Lin","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jmii.2021.03.014_bib13","doi-asserted-by":"crossref","first-page":"e4297","DOI":"10.7717\/peerj.4297","article-title":"Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program","author":"Hu","year":"2018","journal-title":"Peer J"},{"key":"10.1016\/j.jmii.2021.03.014_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.kjms.2016.08.004","article-title":"Hepatitis D virus infections among injecting drug users with and without human immunodeficiency virus infection in Taiwan","volume":"32","author":"Hsieh","year":"2016","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jmii.2021.03.014_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jfma.2018.11.008","article-title":"Taiwan consensus statement on the management of chronic hepatitis B","volume":"118","author":"Chien","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jmii.2021.03.014_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/jmv.25582","article-title":"Decreasing seroprevalence of anti-hepatitis D virus antibodies in the antiviral era with inverse association with hepatitis B virus DNA, Taiwan, 2006 to 2019","volume":"92","author":"Lee","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jmii.2021.03.014_bib17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(95)91558-3","article-title":"Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D","volume":"346","author":"Wu","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2021.03.014_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/339237a0","article-title":"Avoiding false positives with PCR","volume":"339","author":"Kwok","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.jmii.2021.03.014_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5152\/tjg.2020.18846","article-title":"The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D","volume":"31","author":"Abbas","year":"2020","journal-title":"Turk J Gastroenterol"},{"issue":"11","key":"10.1016\/j.jmii.2021.03.014_bib20","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/jgh.15061","article-title":"Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos (t) ides analogues therapy","volume":"35","author":"Jang","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jmii.2021.03.014_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jmii.2021.03.014_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/liv.14356","article-title":"Future treatments for hepatitis delta virus infection","volume":"40","author":"Asselah","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jmii.2021.03.014_bib24","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2021.03.014_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/0003-4819-98-4-437","article-title":"Chronic hepatitis in carriers of Hepatitis B surface antigen, with intrahepatic expression of the delta antigen: an active and progressive disease unresponsive to immunosuppressive treatment","volume":"98","author":"Rizzetto","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jmii.2021.03.014_bib26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cld.2019.04.005","article-title":"HBV\/HDV coinfection: a challenge for therapeutics","volume":"23","author":"Koh","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jmii.2021.03.014_bib27","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in Italy: a long-term cohort study","volume":"53","author":"Niro","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jmii.2021.03.014_bib28","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2004.01.011","article-title":"Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection","volume":"126","author":"Liaw","year":"2004","journal-title":"Gastroenterol"},{"key":"10.1016\/j.jmii.2021.03.014_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00042737-200012060-00019","article-title":"Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study","volume":"12","author":"Huo","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jmii.2021.03.014_bib30","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","article-title":"Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients","volume":"130","author":"Su","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jmii.2021.03.014_bib31","series-title":"Hepatitis Delta virus","first-page":"173","article-title":"Functional and clinical significance of hepatitis D virus genotype II infection","author":"Wu","year":"2006"},{"key":"10.1016\/j.jmii.2021.03.014_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/apt.15521","article-title":"Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia","volume":"51","author":"Palom","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jmii.2021.03.014_bib33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes","volume":"72","author":"Kamal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jmii.2021.03.014_bib34","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/hep.28957","article-title":"A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians","volume":"66","author":"Chen","year":"2017","journal-title":"Hepatology"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118221000669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118221000669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:28:12Z","timestamp":1761658092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118221000669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1684118221000669"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2021.03.014","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2021.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}